This review will trace the steps in the development of pixantrone dimaleate (initial code BBR 2778,
Pixruvi®), an anthracenedione chemotype, as a chemotherapeutic agent. This drug exhibits reduced cardiotoxicity
in comparison to anthracyclines and mitoxantrone. Synthetic pathways, biological evaluations and mechanistic
considerations will be discussed. On May 10, 2012, the European Medicines Agency granted a conditional marketing
approval to CTI Biopharma for pixantrone dimaleate for the treatment of adults suffering from multiple relapsed
or refractory aggressive non-Hodgkin B-cell lymphomas (NHL). Potential applications of pixantrone dimaleate
for the treatment of multiple sclerosis and other maladies will be presented.
Keywords: BBR-2778, cardiotoxicity, non-Hodgkin, lymphoma, pixantrone, Pixuvri®.
Rights & PermissionsPrintExport